| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5648591 | Journal of the American Academy of Dermatology | 2016 | 7 Pages |
Abstract
There was no statistical evidence of greater efficacy for apremilast versus methotrexate. The $187,888 incremental cost per PASI 75 may exceed what payers are willing to pay.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
April W. MD, MPH, Keith A. PhD, Murali PhD, Darren BS, James E. PhD,